US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
WO1986005807A1
(en)
|
1985-04-01 |
1986-10-09 |
Celltech Limited |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5108912A
(en)
|
1987-01-30 |
1992-04-28 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
US5037651A
(en)
|
1987-01-30 |
1991-08-06 |
American Cyanamid Company |
Dihydro derivatives of LL-E33288 antibiotics
|
US5079233A
(en)
|
1987-01-30 |
1992-01-07 |
American Cyanamid Company |
N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
US5268358A
(en)
|
1988-12-08 |
1993-12-07 |
Cor Therapeutics, Inc. |
PDGF receptor blocking peptides
|
US5734033A
(en)
|
1988-12-22 |
1998-03-31 |
The Trustees Of The University Of Pennsylvania |
Antisense oligonucleotides inhibiting human bcl-2 gene expression
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US7144731B2
(en)
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
US20050276784A1
(en)
|
1990-08-27 |
2005-12-15 |
Solan-Kettering Institute For Cancer Research |
Ligand for the c-kit receptor and methods of use thereof
|
US20030125519A1
(en)
|
1990-08-27 |
2003-07-03 |
Peter Besmer |
Ligand for the c-kit receptor and methods of use thereof
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
CA2074825C
(en)
|
1990-12-14 |
2005-04-12 |
Daniel J. Capon |
Chimeric chains for receptor-associated signal transduction pathways
|
JPH06507543A
(ja)
|
1991-01-31 |
1994-09-01 |
コア セラピューティクス,インコーポレイティド |
ヒト血小板由来成長因子レセプターポリペプチドの細胞外領域ドメイン
|
JP3213314B2
(ja)
*
|
1991-04-05 |
2001-10-02 |
ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン |
幹細胞因子レセプターに対するモノクローナル抗体
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4205148A1
(de)
|
1991-05-25 |
1993-01-21 |
Boehringer Mannheim Gmbh |
Monoklonale antikoerper gegen c-kit
|
US5545533A
(en)
|
1991-05-25 |
1996-08-13 |
Boehringer Mannheim Gmbh |
Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5369108A
(en)
|
1991-10-04 |
1994-11-29 |
Sloan-Kettering Institute For Cancer Research |
Potent inducers of terminal differentiation and methods of use thereof
|
USRE38506E1
(en)
|
1991-10-04 |
2004-04-20 |
Sloan-Kettering Institute For Cancer Research |
Potent inducers of terminal differentiation and methods of use thereof
|
US5817310A
(en)
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
NZ246242A
(en)
|
1991-12-02 |
1996-01-26 |
Cor Therapeutics Inc |
Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
|
US5766886A
(en)
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
EP0548867A2
(en)
|
1991-12-23 |
1993-06-30 |
Yeda Research And Development Co. Ltd. |
Soluble stem cell factor (SFC)-receptor
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US6271242B1
(en)
|
1992-02-10 |
2001-08-07 |
Bristol-Myers Squibb Co. |
Method for treating cancer using a tyrosine protein kinase inhibitor
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6001803A
(en)
|
1992-04-23 |
1999-12-14 |
Sloan-Kettering Institute For Cancer Research |
Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
DK1087013T3
(da)
|
1992-08-21 |
2009-05-11 |
Univ Bruxelles |
Immunoglobuliner uden lette kæder
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
KR960703622A
(ko)
|
1993-07-15 |
1996-08-31 |
수잔 포오덴 |
단백질 티로신 키나아제 억제제의 프로드러그(prodrugs of protein tyrosine kinase inhibitors)
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
US5925376C1
(en)
|
1994-01-10 |
2001-03-20 |
Madalene C Y Heng |
Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
|
US5618709A
(en)
|
1994-01-14 |
1997-04-08 |
University Of Pennsylvania |
Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
EP0770135A1
(en)
|
1994-07-29 |
1997-05-02 |
Smithkline Beecham Plc |
Novel compounds
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5911995A
(en)
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
EP1323346B1
(en)
|
1995-01-17 |
2006-06-28 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
GB9501567D0
(en)
|
1995-01-26 |
1995-03-15 |
Pharmacia Spa |
Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
|
US5998596A
(en)
|
1995-04-04 |
1999-12-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibition of protein kinase activity by aptameric action of oligonucleotides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5911988A
(en)
|
1995-04-28 |
1999-06-15 |
Bayer Corporation |
Method for treating asthma using SCF antibody
|
AU5779696A
(en)
|
1995-06-01 |
1996-12-18 |
Kishimoto, Tadamitsu |
Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
US6936259B2
(en)
|
1995-06-08 |
2005-08-30 |
University Of Saskatchewan |
CAMP factor of Streptococcus uberis
|
GB9515975D0
(en)
|
1995-08-04 |
1995-10-04 |
Zeneca Ltd |
Chemical compounds
|
US5863904A
(en)
|
1995-09-26 |
1999-01-26 |
The University Of Michigan |
Methods for treating cancers and restenosis with P21
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
US6127366A
(en)
|
1995-11-22 |
2000-10-03 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
IL123568A
(en)
|
1995-12-08 |
2001-08-08 |
Janssen Pharmaceutica Nv |
History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
DE19600589C1
(de)
|
1996-01-10 |
1997-01-16 |
Univ Eberhard Karls |
Antikörper A3C6E2
|
US5958769A
(en)
|
1996-01-18 |
1999-09-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for mediating cell cycle progression
|
US6090948A
(en)
|
1996-01-30 |
2000-07-18 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000504014A
(ja)
|
1996-01-30 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質転移酵素の阻害剤
|
AU5711196A
(en)
|
1996-03-14 |
1997-10-01 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
CN1107072C
(zh)
|
1996-03-22 |
2003-04-30 |
人类基因组科学公司 |
编程性细胞死亡诱导分子ⅱ
|
US5882644A
(en)
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
US5891889A
(en)
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5883105A
(en)
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US5910417A
(en)
|
1996-05-31 |
1999-06-08 |
National Jewish Center For Immunology And Respiratory Medicine |
Regulation of cytokine production in a hematopoietic cell
|
US5648239A
(en)
|
1996-06-21 |
1997-07-15 |
Incyte Pharmaceuticals, Inc. |
Human camp-dependent protein kinase inhibitor homolog
|
WO1997049700A1
(en)
|
1996-06-27 |
1997-12-31 |
Pfizer Inc. |
Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
|
NZ513800A
(en)
|
1996-08-12 |
2001-09-28 |
Welfide Corp |
Treatment of diseases using Rho kinase inhibitors
|
US6030982A
(en)
|
1996-09-13 |
2000-02-29 |
Schering Corporationm |
Compounds useful for inhibition of farnesyl protein transferase
|
US5945429A
(en)
|
1996-09-13 |
1999-08-31 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6040305A
(en)
|
1996-09-13 |
2000-03-21 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US5885834A
(en)
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
CA2266629C
(en)
|
1996-10-01 |
2002-04-16 |
Cima Labs Inc. |
Taste-masked microcapsule compositions and methods of manufacture
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
US6093737A
(en)
|
1996-12-30 |
2000-07-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6013662A
(en)
|
1996-12-30 |
2000-01-11 |
Rhone-Poulenc Rorer S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US5939439A
(en)
|
1996-12-30 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6414145B1
(en)
|
1997-01-29 |
2002-07-02 |
Zeneca Limited |
Imidazolyl compounds as inhibitors of farnesyl-protein tranferase
|
ZA981080B
(en)
|
1997-02-11 |
1998-08-12 |
Warner Lambert Co |
Bicyclic inhibitors of protein farnesyl transferase
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
WO1998041090A1
(en)
|
1997-03-19 |
1998-09-24 |
Yale University |
Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US6211193B1
(en)
|
1997-06-17 |
2001-04-03 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6051582A
(en)
|
1997-06-17 |
2000-04-18 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6228865B1
(en)
|
1997-06-17 |
2001-05-08 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6239140B1
(en)
|
1997-06-17 |
2001-05-29 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6225322B1
(en)
|
1997-06-17 |
2001-05-01 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6159984A
(en)
|
1997-06-17 |
2000-12-12 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
DE19727814C1
(de)
|
1997-06-30 |
1998-10-01 |
Univ Eberhard Karls |
Anitkörper 4G8B4B12
|
TR200000415T2
(tr)
|
1997-08-15 |
2000-08-21 |
Cephalon Inc. |
Prostat kanserinin tedavi edilmesi için birleşimler.
|
US7361336B1
(en)
|
1997-09-18 |
2008-04-22 |
Ivan Bergstein |
Methods of cancer therapy targeted against a cancer stem line
|
US6555367B1
(en)
|
1997-10-10 |
2003-04-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Complex of biotinylated viral vector and ligand for targeted gene delivery
|
US6103723A
(en)
|
1997-10-17 |
2000-08-15 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
ATE205195T1
(de)
|
1997-10-22 |
2001-09-15 |
Astrazeneca Ab |
Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
|
EP1025089A1
(en)
|
1997-10-22 |
2000-08-09 |
Zeneca Limited |
Imidazole derivatives and their use as farnesyl protein transferase inhibitors
|
WO1999023105A1
(en)
|
1997-11-03 |
1999-05-14 |
Human Genome Sciences, Inc. |
Vegi, an inhibitor of angiogenesis and tumor growth
|
US6124465A
(en)
|
1997-11-25 |
2000-09-26 |
Rhone-Poulenc S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
ES2193590T3
(es)
|
1997-11-28 |
2003-11-01 |
Lg Chemical Ltd |
Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.
|
US6054466A
(en)
|
1997-12-04 |
2000-04-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6242196B1
(en)
|
1997-12-11 |
2001-06-05 |
Dana-Farber Cancer Institute |
Methods and pharmaceutical compositions for inhibiting tumor cell growth
|
US6335156B1
(en)
|
1997-12-18 |
2002-01-01 |
The Johns Hopkins University School Of Medicine |
14-3-3σ arrests the cell cycle
|
JP3283032B2
(ja)
|
1998-02-02 |
2002-05-20 |
エルジ ケミカル リミテッド |
ピペリジン構造を有するファネシル転移酵素阻害剤及びその製造方法
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
DK2180007T4
(da)
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
NZ507165A
(en)
|
1998-04-27 |
2003-06-30 |
Warner Lambert Co |
Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
|
JP2002512776A
(ja)
|
1998-04-28 |
2002-05-08 |
スミスクライン・ビーチャム・コーポレイション |
免疫原性の低下したモノクローナル抗体
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
HU229358B1
(en)
|
1998-07-06 |
2013-11-28 |
Janssen Pharmaceutica Nv |
Farnesyl protein transferase inhibitors for treating arthropathies
|
US6034053A
(en)
|
1998-07-13 |
2000-03-07 |
Wayne Hughes Institute |
EGF-isoflavone conjugates for the prevention of restenosis
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
US6372747B1
(en)
|
1998-12-18 |
2002-04-16 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6362188B1
(en)
|
1998-12-18 |
2002-03-26 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
FR2787327B1
(fr)
|
1998-12-21 |
2003-01-17 |
Aventis Pharma Sa |
Compositions contenant des inhibiteurs de farnesyle transferase
|
US6432959B1
(en)
|
1998-12-23 |
2002-08-13 |
Schering Corporation |
Inhibitors of farnesyl-protein transferase
|
WO2000042042A2
(en)
|
1999-01-11 |
2000-07-20 |
Princeton University |
High affinity inhibitors for target validation and uses thereof
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
US6245759B1
(en)
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
WO2000061637A1
(en)
|
1999-04-14 |
2000-10-19 |
Smithkline Beecham Corporation |
Erythropoietin receptor antibodies
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US6143766A
(en)
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
US6576812B1
(en)
|
1999-05-06 |
2003-06-10 |
The Trustees Of Columbia University In The City Of New York |
Compound screening assays using a transgenic mouse model of human skin diseases
|
US6989248B2
(en)
|
1999-05-06 |
2006-01-24 |
The Trustees Of Columbia University In The City Of New York |
Methods of use of compounds which inhibit the stem cell signaling pathway
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
EP1094110A1
(en)
|
1999-10-21 |
2001-04-25 |
Leadd B.V. |
Apoptosis inducing proteinaceous substance
|
AU1364701A
(en)
|
1999-11-12 |
2001-06-06 |
Advanced Research And Technology Institute, Inc. |
Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1)
|
DE60042789D1
(de)
|
1999-11-29 |
2009-10-01 |
Bac Ip B V |
Immobilisierte antigenbindende moleküle aus einer domäne
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
US6403581B1
(en)
|
2000-01-19 |
2002-06-11 |
American Cyanamid Company |
Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US8088060B2
(en)
|
2000-03-15 |
2012-01-03 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
TWI318983B
(en)
*
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
US20110091428A1
(en)
|
2000-07-31 |
2011-04-21 |
New York Medical College |
Compositions of adult organ stem cells and uses thereof
|
EP3263702A1
(en)
|
2000-10-06 |
2018-01-03 |
Kyowa Hakko Kirin Co., Ltd. |
Cells producing antibody compositions
|
EP1333032A4
(en)
|
2000-10-06 |
2005-03-16 |
Kyowa Hakko Kogyo Kk |
METHOD FOR PURIFYING ANTIBODIES
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US6914947B2
(en)
|
2001-02-28 |
2005-07-05 |
Telefonaktiebolaget L M Ericsson (Publ) |
Method and apparatus for handling time-drift
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
JP4297689B2
(ja)
|
2001-04-13 |
2009-07-15 |
中外製薬株式会社 |
抗原の発現量を定量する方法
|
EP2298809A3
(en)
|
2001-07-12 |
2012-02-15 |
FOOTE, Jefferson |
Super humanized antibodies
|
MXPA04001072A
(es)
|
2001-08-03 |
2005-02-17 |
Glycart Biotechnology Ag |
Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
|
ES2376422T3
(es)
|
2001-08-21 |
2012-03-13 |
Ventana Medical Systems, Inc. |
Método y ensayo de cuantificación para determinar el estado c-kit/scf/pakt.
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
WO2003054216A2
(en)
|
2001-12-20 |
2003-07-03 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
AU2003237332A1
(en)
|
2002-06-03 |
2003-12-19 |
Centocor, Inc. |
Anti-relp fusion antibodies, compositions, methods and uses
|
AU2003245752A1
(en)
|
2002-06-28 |
2004-01-19 |
Bio Transplant, Inc. |
Process for promoting graft acceptance by depletion of hematopoietic stem cells
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
CN101987871A
(zh)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
US7705045B2
(en)
|
2002-11-14 |
2010-04-27 |
Syntarga, B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
CN1767852B
(zh)
|
2003-01-31 |
2010-04-14 |
塞尔德克斯医疗公司 |
抗体疫苗缀合物及其用途
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
DE602004027888D1
(de)
|
2003-02-20 |
2010-08-12 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihr
|
US20050281828A1
(en)
|
2003-03-04 |
2005-12-22 |
Bowdish Katherine S |
Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
AU2004280333A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Llc |
Humanization of antibodies
|
US7303893B1
(en)
|
2003-08-28 |
2007-12-04 |
Takeda San Diego, Inc. |
Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US20050226867A1
(en)
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
WO2005040170A2
(en)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
EP1690097A2
(en)
|
2003-12-04 |
2006-08-16 |
Applied Research Systems ARS Holding N.V. |
Methods for identifying modulators of active kit tyrosine kinase receptor
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
EP1720881B9
(en)
|
2004-03-01 |
2013-04-17 |
Spirogen Sàrl |
11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
PL1730315T3
(pl)
|
2004-03-27 |
2010-03-31 |
Klein Hanns Georg |
Polimorfizmy w genie NOD2/CARD15
|
ES2375481T3
(es)
|
2004-03-30 |
2012-03-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
|
AU2005249396B2
(en)
|
2004-05-05 |
2011-10-20 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
GB0410725D0
(en)
|
2004-05-13 |
2004-06-16 |
Spirogen Ltd |
Pyrrolobenzodiazepine therapeutic agents
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
US7329495B2
(en)
|
2004-06-09 |
2008-02-12 |
Board Of Regents, The University Of Texas System |
Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
|
AU2005271892A1
(en)
|
2004-07-10 |
2006-02-16 |
Alexion Pharmaceuticals, Inc. |
Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
|
WO2006012688A1
(en)
|
2004-08-02 |
2006-02-09 |
Amrad Operations Pty Ltd |
A method of treating cancer comprising a vegf-b antagonist
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
RU2007108716A
(ru)
|
2004-09-10 |
2008-10-20 |
Вайет (Us) |
Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
|
WO2006132670A2
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
RU2007135216A
(ru)
|
2005-02-23 |
2009-03-27 |
Мерримак Фармасьютикалз, Инк. (Us) |
Биспецифические связывающие агенты для модулирования биологической активности
|
US20060222634A1
(en)
|
2005-03-31 |
2006-10-05 |
Clarke Diana L |
Amnion-derived cell compositions, methods of making and uses thereof
|
DE602006011300D1
(de)
|
2005-04-21 |
2010-02-04 |
Spirogen Ltd |
Pyrrolobenzodiazepine
|
DK1874821T3
(da)
|
2005-04-26 |
2013-07-08 |
Trion Pharma Gmbh |
Kombination af antistoffer med glykokortikoider til behandling af kræft
|
WO2007004060A2
(en)
|
2005-05-05 |
2007-01-11 |
Valorisation Hsj, Societe En Commandite |
Cytokine receptor modulators and uses thereof
|
US20090136450A1
(en)
|
2005-08-01 |
2009-05-28 |
Ares Trading S.A. |
Therapy for neurological diseases
|
EP1909846B1
(en)
|
2005-08-05 |
2018-12-26 |
Syntarga B.V. |
Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
|
AU2006294554B2
(en)
|
2005-09-26 |
2013-03-21 |
E. R. Squibb & Sons, L.L.C. |
Antibody-drug conjugates and methods of use
|
WO2008048671A1
(en)
|
2006-10-18 |
2008-04-24 |
University Of Illinois |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
ATE427949T1
(de)
|
2005-10-05 |
2009-04-15 |
Spirogen Ltd |
4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
|
AU2006304876B2
(en)
|
2005-10-21 |
2013-04-18 |
Regents Of The University Of California |
c-KIT oncogene mutations in melanoma
|
SI1945665T1
(sl)
|
2005-10-21 |
2012-03-30 |
Genzyme Corp |
Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
WO2007084949A2
(en)
|
2006-01-18 |
2007-07-26 |
The Uab Research Foundation |
Modulators of cardiac cell hypertrophy and hyperplasia
|
MX2008009956A
(es)
|
2006-02-02 |
2008-12-12 |
Syntarga Bv |
Analogos de cc-1065 solubles en agua y sus conjugados.
|
CN102861338A
(zh)
|
2006-04-05 |
2013-01-09 |
诺瓦提斯公司 |
用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
|
TWI395754B
(zh)
*
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007143146A2
(en)
|
2006-05-31 |
2007-12-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of treating inflammatory diseases using tyroskine kinase inhibitors
|
EP2044118A2
(en)
|
2006-06-13 |
2009-04-08 |
Zymogenetics, Inc. |
Il-17 and il-23 antagonists and methods of using the same
|
ES2413087T3
(es)
*
|
2006-06-13 |
2013-07-15 |
Oncomed Pharmaceuticals, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento del cáncer
|
CN101516191A
(zh)
|
2006-09-28 |
2009-08-26 |
默克公司 |
Saha的胺碱盐和其多晶型物
|
US7959942B2
(en)
|
2006-10-20 |
2011-06-14 |
Orbusneich Medical, Inc. |
Bioabsorbable medical device with coating
|
EP2076513A1
(en)
|
2006-10-20 |
2009-07-08 |
Irm Llc |
Compositions and methods for modulating c-kit and pdgfr receptors
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
EP3255061B1
(en)
|
2006-11-03 |
2021-06-16 |
The Board of Trustees of the Leland Stanford Junior University |
Selective immunodepletion of endogenous stem cell niche for engraftment
|
EP2083830A1
(en)
|
2006-11-17 |
2009-08-05 |
Innate Pharma |
Improved methods of using phosphoantigen for the treatment of cancer
|
US20100143935A1
(en)
|
2006-12-01 |
2010-06-10 |
Apocell, Inc. |
c-KIT Phosphorylation in Cancer
|
AU2008226824A1
(en)
|
2007-03-12 |
2008-09-18 |
Board Of Regents Of The University Of Texas System |
Use of EphB4 as a diagnostic marker and a therapeutic target for ovarian cancer
|
ES2395114T3
(es)
|
2007-03-27 |
2013-02-08 |
Synta Pharmaceuticals Corporation |
Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90
|
US20110268776A1
(en)
|
2007-04-25 |
2011-11-03 |
Schapira Jay N |
Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
WO2008150261A1
(en)
|
2007-06-04 |
2008-12-11 |
Wyeth |
Detection and quantitation of calicheamicin
|
EP2155238B1
(en)
|
2007-06-05 |
2016-04-06 |
Yale University |
Antibody against d4 domain of the kit receptor and use thereor
|
WO2009017394A1
(en)
|
2007-08-01 |
2009-02-05 |
Syntarga B.V. |
Substituted cc-1065 analogs and their conjugates
|
JP5703466B2
(ja)
|
2007-08-07 |
2015-04-22 |
パーデュー・リサーチ・ファウンデーションPurdue Research Foundation |
キナーゼ阻害薬およびその使用
|
US20100196923A1
(en)
|
2007-08-14 |
2010-08-05 |
Anthony Atala |
Pluripotent adult stem cells
|
US7538395B2
(en)
|
2007-09-21 |
2009-05-26 |
Semiconductor Components Industries, L.L.C. |
Method of forming low capacitance ESD device and structure therefor
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
JP2011504926A
(ja)
|
2007-11-28 |
2011-02-17 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
Egfrキナーゼ阻害剤とc−kit阻害剤による併用治療
|
ES2614284T3
(es)
|
2007-11-30 |
2017-05-30 |
Glaxo Group Limited |
Construcciones de unión a antígenos
|
WO2009082624A2
(en)
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
WO2009079585A2
(en)
|
2007-12-17 |
2009-06-25 |
Dyax Corp. |
Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
|
CA2711256C
(en)
|
2008-01-03 |
2019-01-15 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
US8426396B2
(en)
|
2008-01-08 |
2013-04-23 |
Shriners Hospitals For Children |
Treatment for achondroplasia
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
WO2009135001A2
(en)
|
2008-04-30 |
2009-11-05 |
University Of Pittsburgh- Commonwealth System Of Higher Education |
Methods and compositions for regulating th2 and th17 responses
|
EP2297305A4
(en)
|
2008-05-15 |
2013-03-13 |
Univ Miami |
ISOLATION OF STEM CELL PRECURSORS AND EXPANSION UNDER NON-ADHESION CONDITIONS
|
CN102065859B
(zh)
|
2008-06-13 |
2012-10-03 |
诺瓦提斯公司 |
用于神经纤维瘤病的取代的苯并咪唑类
|
CN105726542A
(zh)
|
2008-06-27 |
2016-07-06 |
印第安纳大学研究与技术公司 |
用于抑制和/或治疗神经纤维瘤及相关肿瘤的材料和方法
|
WO2010001908A1
(ja)
|
2008-06-30 |
2010-01-07 |
協和発酵キリン株式会社 |
抗cd27抗体
|
WO2010017480A1
(en)
|
2008-08-07 |
2010-02-11 |
Centrose, Llc |
Glycoside compounds and pharmaceutical compositions thereof
|
EP2340305A1
(en)
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
WO2010036373A2
(en)
|
2008-09-26 |
2010-04-01 |
Duke University |
Hematopoietic stem cell growth factor
|
MX2011004165A
(es)
|
2008-10-22 |
2011-08-08 |
Genentech Inc |
Celulas madre de prostata y sus usos.
|
PT2344478T
(pt)
|
2008-11-03 |
2017-11-28 |
Syntarga Bv |
Análogos de cc-1065 e seus conjugados
|
JP5869342B2
(ja)
|
2008-11-19 |
2016-02-24 |
アンスロジェネシス コーポレーション |
羊膜由来接着細胞
|
US20110281813A1
(en)
|
2008-12-04 |
2011-11-17 |
Cleveland Clinic |
Method of treating c-kit positive relapsed acute myeloid leukemia
|
US20100204058A1
(en)
|
2009-01-28 |
2010-08-12 |
Howard Yuan-Hao Chang |
Profiling for Determination of Response to Treatment for Inflammatory Disease
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
NZ596274A
(en)
*
|
2009-05-12 |
2013-11-29 |
Pfizer |
Blocking anti-dkk-1 antibodies and their uses
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
EP2435067A2
(en)
|
2009-05-28 |
2012-04-04 |
Glaxo Group Limited |
Stem cell targeting
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
US8470980B2
(en)
|
2009-09-09 |
2013-06-25 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
CA2780190C
(en)
|
2009-11-06 |
2020-05-05 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
US10817851B2
(en)
|
2009-12-23 |
2020-10-27 |
Aristocrat Technologies Australia Pty Limited |
System and method for cashless gaming
|
RU2012132470A
(ru)
|
2009-12-29 |
2014-02-10 |
Йейл Юниверсити |
Ингибиторы рецепторов фактора роста эндотелия сосудов (vegf) и способы их применения
|
US20120328599A1
(en)
|
2010-01-14 |
2012-12-27 |
Yale University |
Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
|
US20130011406A1
(en)
|
2010-03-26 |
2013-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
AU2012204846B2
(en)
|
2011-01-06 |
2016-09-08 |
Complix Nv |
Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
AR086044A1
(es)
*
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
US11135303B2
(en)
|
2011-10-14 |
2021-10-05 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
KR102268351B1
(ko)
|
2012-07-25 |
2021-06-22 |
셀덱스 쎄라퓨틱스, 인크. |
항-kit 항체 및 그의 용도
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
WO2015112822A1
(en)
|
2014-01-24 |
2015-07-30 |
Kolltan Pharmaceuticals, Inc. |
Antibody-drug conjugates targeting kit receptor and uses thereof
|
EP3145543A4
(en)
|
2014-05-23 |
2017-12-13 |
Celldex Therapeutics, Inc. |
Treatment of eosinophil or mast cell related disorders
|
MX2017001565A
(es)
|
2014-08-06 |
2017-04-27 |
Pfizer |
Compuestos de imidazopiridazina.
|
US11392902B2
(en)
|
2017-06-06 |
2022-07-19 |
United Parcel Service Of America, Inc. |
Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
|